Navigation Links
Fuisz Tobacco Announces Clinical Study Results for Fuisz Tobacco Sheet Strip; Super Enhanced Bioavailability of Nicotine From Its Tobacco Sheet Strip Supports Efficacy of Low Dose Tobacco Product
Date:5/20/2008

WASHINGTON, May 20 /PRNewswire-USNewswire/ -- Fuisz Tobacco today announces the results of a cross-over clinical study comparing the absorption of nicotine from the use of Fuisz Tobacco's dissolving tobacco strip and the use of a nicotine 2mg chewing gum -- the study's control.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080115/CLTU066 )

The results demonstrate extraordinary nicotine bioavailability for the Fuisz Tobacco strip. A Fuisz Tobacco strip containing 75 mg's of tobacco delivered substantially higher peak nicotine plasma concentration than the 2 mg nicotine chewing gum control product. This suggests that the Fuisz Tobacco strip delivers nicotine more than five times more effectively than the SNUS tobacco format, which is considered to represent the most efficacious smokeless tobacco format for nicotine delivery currently available.

The study design was based upon the Lunell study of Swedish SNUS nicotine absorption. The Lunell study is part of the so called Gothiatek(R) standards developed by leading SNUS marketer Swedish Match.

Joseph Fuisz, Fuisz Tobacco's Managing Member commented: "These study results represent a remarkable advance for smokeless tobacco. By delivering tobacco satisfaction from a dramatically smaller amount of tobacco, we can substantially lower the amount of tobacco used in the adult consumer friendly Fuisz Tobacco strip. This news should be welcomed by the harm reduction community, the tobacco industry, and adult smokers alike."

Fuisz Tobacco's Founding Member, Richard Fuisz, M.D., stated: "We have a new concept here. The Fuisz Tobacco strip is not a cigarette and yet the user gets nicotine from its tobacco. This is not a pouch that does not efficiently transfer nicotine and then must be removed from the mouth and is environmentally as damaging as a cigarette. This gives off no smoke and is unaffected by smoking bans. This is not an ill tasting lozenge. This is in fact the new way for adult tobacco users to gain satisfaction in a simple straightforward manner. Easier to use than SNUS, a small strip is simply placed in the cheek and allowed to dissolve."

Joseph Fuisz, continued: "It is important to understand that the Fuisz Tobacco strip's super bioavailability is used to lower the amount of tobacco contained in our smokeless product, and not to develop ever-higher nicotine plasma concentrations. The Fuisz tobacco strip offers not only excellent tobacco satisfaction but is a great tasting product that appeals greatly to the vast majority of adult smokers, most of whom are not inclined to use existing smokeless tobacco products."

The clinical study was performed by an independent contract research organization that serves the pharmaceutical industry.

The Fuisz Tobacco smokeless tobacco product is a tobacco containing sheet, similar in appearance to a Listerine(R) PocketPak(R) breath strip but substantially thicker and taking longer to dissolve. The Fuisz Tobacco strip is spitless and dissolves entirely in the cheek. This means that the product can be discretely consumed in a social setting without residue to remove from the mouth after use -- unlike traditional smokeless tobacco products. Fuisz Tobacco's tobacco strip technology is protected by multiple patents pending and licenses.

Fuisz Tobacco is a private company. Its founding partner, Richard C. Fuisz, M.D., is a noted pharmaceutical inventor, including in the thin film drug delivery, quick dissolve tablet, taste masking and controlled release fields (http://www.en.wikipedia.org/wiki/Richard_Fuisz). Fuisz Tobacco's managing partner, Joseph Fuisz, is a corporate lawyer and is a named inventor on over forty thin film drug delivery patents issued and pending. Mr. Fuisz previously served as Senior Vice President for Business Development of MonoSol Rx (http://www.monosolrx.com). He is a graduate of Yale College and the Columbia Law School.


'/>"/>
SOURCE Fuisz Tobacco
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
2. Ipsogen Announces Three Studies at the American Society of Clinical Oncology (ASCO) Meeting Extending the Utility of the Genomic Grade Index for Predicting Response to Chemotherapy in Breast Cancer
3. TAP Pharmaceutical Products Inc. Announces Phase 3 TAK-390MR Data Demonstrating Higher Overall Healing Versus Lansoprazole in Patients with Erosive Esophagitis
4. Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials
5. GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab)
6. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
7. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
8. BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting
9. IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program
10. Biopure Announces Publication of Phase II Proof-of-Concept Coronary Trial
11. Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Feb. 23, 2017 Regulus ... the discovery and development of innovative medicines targeting microRNAs, ... year 2016 financial results on Thursday, March 2, 2017 ... a conference call and webcast on March 2, 2017 ... and full year 2016 financial results and provide a ...
(Date:2/23/2017)... The fast-growing cannabis market is expected to create ... According to the 2017 Legal Marijuana Outlook, published by New ... jobs by 2020, with an implied growth rate of more ... accelerating pace of cannabis legalization is considered as the main ... will further create more business ventures and boost the economy. ...
(Date:2/23/2017)... 2017 LG Innotek today announced that the company has ... its sterilization performance is 1.5 times higher than the competitor,s 45mW ... in the range of 200 -- 280nm, allowing it to be used ... their DNA. LG Innotek,s product emits UV in the range of ... Until now, ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... 24, 2017 , ... The California State University Institute for Palliative Care ... or interested in palliative care education and research. The Symposium, “Innovate. Investigate. Educate: ... San Diego on Sept. 28 and 29, 2017, on the campus of California State ...
(Date:2/24/2017)... ... , ... The Radiology Business Management Association will select the 2017 ... Building Better Radiology Marketing Programs conference, held this year from March 5 ... awards are given out in five categories. They are:, ,     Patient ...
(Date:2/23/2017)... ... 23, 2017 , ... Thinksport, the most award-winning sunscreen on ... of Marin. For the second year in a row, cyclists will stay protected ... are thrilled to provide our safe, non-toxic sunscreen to over 2,000 cycling enthusiasts ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rare Disease Report®, which ... participating in Rare Disease Day events, hosted by the Rare Disease Legislative Advocates ... a website, weekly e-newsletter and quarterly publication, will be conducting interviews with patients ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... thought leadership , media relations, content marketing, social media management, corporate communications, ... clients already in the state and in nearby New Hampshire, Massachusetts and Canada, ...
Breaking Medicine News(10 mins):